MCL1 and glioma: These findings are promising as they suggest a proof-of-principle that the combined inhibition of Mcl-1-related chaperones in combination with selective Bcl-2/Bcl-xL inhibitors may be a suitable approach to combat the most resistant phenotypes of gliomas and potentially other entities.